Articles

IU surgeon gets $2 million for heart pump

IU School of Medicine associate professor Mark Rodefeld will use funding to further develop the pump, intended to combat a congenital heart defect that kills many children in their first year of life.

Read More

After health reform, Lilly looking for more

The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.

Read More

Lilly halts development of Alzheimer’s drug

Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.

Read More

Lilly’s Alzheimer’s gamble takes aim at $10 billion in patent losses

Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.

Read More

Q&A

David Stocum is the director of the Center for Regenerative Biology and Medicine at the IUPUI School of Science.
He and his team are studying how amphibians regenerate parts of their bodies to see if there are ways to induce humans to
regenerate tissue that is lost or damaged. The center has about 20 researchers and funding of about $14 million to fuel its
quest.

Read More

Harlan Labs names new CEO

The Indianapolis-based provider of clinical research animals has promoted senior manager Hans Thunem to its top spot.

Read More

Medical device startup FlowCo enlists Guidant alums

The upstart developer of a device to help doctors choose the right-sized stent to prop open clog-prone arteries has brought
aboard former Guidant Corp. executives, including Bill McConnell. Their regulatory and marketing expertise could help FlowCo Inc. bring its artery-measurement
product to market as soon as 2011.

Read More

Roche taps new local CEO

Roche Diagnostics named a new CEO for its North American operations Tuesday to replace Michael Tillmann, who resigned on Friday.

Read More

Company’s medical device earns expedited review

FAST Diagnostics LLC said initial human trials on its method to measure kidney function faster and more accurately than existing
techniques could begin as early as next year, with commercialization following by 2012.

Read More